IDH1 and glioma: IDH1/2 mutations are druggable targets and are already exploited for therapeutic purposes in gliomas, cholangiocarcinoma, and acute myeloid leukemia (AML) [28,35], but, as we will see later, their significance as targets in CS clinical management is still under evaluation.